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Abstract: Purpose: A pilot study to determine whether topical prostaglandin analogues alter the expression of 
conjunctival inflammatory markers in patients with uveitic glaucoma. 
Methods: Prospective, single-masked case series of 20 patients with uveitis and secondary raised intraocular pressure. 
Participants were divided into four groups of five patients dependent on their use of topical medication: (1) prostaglandin 
analogues only, (2) corticosteroids only, (3) both prostaglandin analogues and corticosteroids, (4) no topical medication. 
Conjunctival cells were harvested by impression cytology and were examined for inflammatory markers (CD3, CD54, 
HLA-DR, CCR4, CCR5) by flow cytometry. A tear fluid sample was also examined for inflammatory cytokines (IL-
12p70, IL-2, IL-10, IL-8, IL-6, IL-4, IL-5, IFN-gamma, IL-1beta, IFN-alpha, IFN-beta) by multiplex bead arrays. 
Results: All groups demonstrated increased markers of conjunctival inflammation. There was no significant difference in 
levels of any inflammatory markers between the four groups, suggesting that the use of topical prostaglandin analogues 
does not increase conjunctival levels of inflammation beyond those already seen in uveitis 
Conclusions: The use of topical prostaglandins does not appear to induce conjunctival inflammation over that which is 
already present in patients with uveitic glaucoma. This supports the use of topical prostaglandin analogues in patients with 
uveitic glaucoma, indicating that their use is unlikely to adversely affect subsequent glaucoma filtration surgery through 
the induction of chronic conjunctival inflammation. 
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INTRODUCTION 
 Secondary glaucoma is seen in about 10-20% of patients 
attending a uveitis clinic and occurs in combination with all 
types of uveitis [1-4]. In spite of aggressive medical therapy, 
progressive visual field loss and optic nerve damage can 
occur in up to a third of patients, requiring surgical 
intervention in the form of trabeculectomy or tube drainage 
surgery [5]. It is known that chronic use of topical 
antiglaucoma medication is associated with an increased rate 
of failure of trabeculectomy in primary open angle glaucoma 
[6, 7], but whether this is significant in uveitic glaucoma is 
unknown. 
 The prostaglandin analogues are a group of compounds 
that have become the most frequently used ocular 
hypotensive drugs owing to their efficiency in reducing 
intraocular pressure and the low incidence rate and severity 
of adverse events, in particular in the absence of systemic 
side effects, especially in comparison to the beta-blockers [8-
10]. However, they are pro-inflammatory, at least in theory,  
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and cause conjunctival side-effects including hyperaemia, in 
10-60% of cases [8, 9, 11-14]. 
 The purpose of this pilot study was to address the effects 
of prostaglandin analogues on the expression of 
inflammatory markers on the conjunctival epithelium and 
tear film in patients who suffer from uveitis, in order to 
determine whether these drugs are likely to adversely 
prejudice subsequent trabeculectomy surgery in this group. 
METHODS 
 This pilot study was a prospective, single-masked, 
comparative case series of 20 patients with an underlying 
diagnosis of non-infectious uveitis and secondary raised 
intraocular pressure. The study was approved by the UCLH 
Research Ethics Committee (06/Q0512/10). Patients were 
recruited into four groups on the basis of their use of topical 
medication (topical prostaglandins only; topical corticosteroids 
only; both topical prostaglandins and topical corticosteroids; 
and no drops, which served as a control group). Topical 
medication used by patients enrolled in this study included the 
corticosteroids G. Dexamethasone 0.1% (Maxidex, Alcon, 
London, UK) and G. Rimexolone 1% (Vexol, Alcon, London, 
UK), and the prostaglandin analogues G. Latanoprost 0.003% 
(Xalatan, Pfizer, Surrey, UK) and G. Travoprost 50 ?g/ml 
(Travatan, Alcon, London, UK). 
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 The topical corticosteroid groups were enrolled in order 
to determine the impact of topical corticosteroids on 
cytokine expression, both with and without concomitant 
prostaglandin administration. In order to increase the 
probability that the results reflected current treatment, 
patients were excluded if they were on other topical or 
systemic medication, or if their topical medication had not 
been stable for at least one month. Five patients were 
enrolled into each group. 
 Both conjunctival cells and tear samples were tested in 
order to improve the likelihood of detecting any differences 
between the groups. Both the sampling and the laboratory 
tests were performed by a single investigator masked as to 
the groups. A tear fluid sample was obtained prior to 
impression cytology by capillary tube (Drummond Scientific 
Co., Broomall, PA, US) and stored at -70°C. Conjunctival 
cells were then harvested by impression cytology as 
described by Baudouin [15] using 0.20 ?m polyether-sulfone 
filter papers (Supor 200, Pall Corporation, UK). Two pieces 
of filter paper measuring 13mm x 6.5mm were applied to the 
superior bulbar conjunctiva for 15 seconds after application 
of local anaesthetic drops and then fixed in 0.05% 
paraformaldehyde. 
 Conjunctival cells were obtained by spinning down the 
cells from the filters. Cells were divided and stained with 
directly conjugated antibodies to CD3
FITC
, CD54
PE
, HLA-
DR
PerCP
, CCR4
PE
 and CCR5
FITC
 (Becton Dickinson, Cowley, 
UK). They were then examined by flow cytometry using a 
Becton Dickinson FACSCalibur machine (BD, San Jose, 
CA, US). A minimum of 1,000 counts was considered to be 
acceptable and at least this number was collected per sample. 
Data was analyzed using Winlist (Verity, USA) 
 Tear samples were then examined for inflammatory 
cytokines using the same FACSCalibur flow cytometer. A 
multiplex kit (Bender Medsystems, Austria) was used 
according to manufacturer’s instructions and the data 
analyzed using their dedicated software in order to detect 
expression of IL-12p70, IL-2, IL-10, IL-8, IL-6, IL-4, IL-5, 
IFN-?, IL-1beta, IFN-? and IFN-?. Kruskal Wallis tests were 
used to compare the surface expression levels and cytokine 
levels between the four groups. 
RESULTS 
 We first examined the results of impression cytology of 
the conjunctiva. All of the inflammatory markers measured 
(CD3, CD54, HLADR, CCR4 and CCR5) were found to be 
increased above normal levels in all of the groups, but there 
was no significant difference in the levels seen between any 
of the groups (Fig. 1), suggesting that neither topical 
prostaglandins nor topical corticosteroids have a significant 
additional effect on conjunctival surface markers of 
inflammation in patients with uveitis. This supports the 
conclusion that topical prostaglandins do not significantly 
increase conjunctival inflammation in these patients. 
 Similar results were seen from the examination of the 
tear fluid (Fig. 2). Increased expression of inflammatory 
markers was seen in all the groups, but there was no 
significant increase seen in the groups taking topical 
prostaglandins. This again supports the conclusion that 
topical prostaglandins do not significantly increase 
 
Fig. (1). Conjunctival markers of inflammation. Conjunctival cells were obtained by impression cytology, stained and assessed by flow 
cytometry. Nil, no topical medication; PG, prostaglandin analogues only; CS, corticosteroids only; PG+CS, prostaglandin analogues and 
corticosteroids concurrently. The mean ± the standard error of the mean of the flow cytometric event counts obtained is presented. There 
were no statistically significant differences between the groups. 
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conjunctival inflammation. 
DISCUSSION 
 Prostaglandin analogues have always been used with 
some circumspection in uveitic glaucoma as there have been 
some reports of exacerbation of uveitis and macular oedema 
[16], although larger case series have found no evidence of a 
link [17]. Nevertheless, it is clear that the prostaglandin 
analogues do cause significant conjunctival hyperaemia [14] 
and are also potentially proinflammatory [11-13]. They also 
contain benzalkonium chloride (BAK) as a preservative, 
which may influence the topical tolerance of these drugs: 
BAK induces subclinical toxicity and inflammation on the 
ocular surface and is a major factor responsible for eye drop 
toxicity in long-term use [11, 18]. 
 Conjunctival inflammation is a potential issue in uveitic 
glaucoma as chronic use of antiglaucoma medication is 
associated with trabeculectomy failure in primary open-angle 
glaucoma [6, 7], although the reasons for this have not been 
clearly identified. This study was designed to determine 
whether prostaglandin analogues are associated with 
increased levels of conjunctival inflammation in patients 
with uveitic glaucoma, which would suggest that their use is 
less desirable in a patient population that is at an increased 
risk of needing subsequent trabeculectomy surgery. 
 
 We found increased expression of inflammatory markers 
in the impression cytology specimens taken from patients, 
including HLA-DR, CD54, CCR3 and CCR4, irrespective of 
the topical medication they were taking. Similar results were 
seen in the tear film samples that were analysed. Thus it 
appears that increased expression of conjunctival markers of 
inflammation and tear film cytokines is primarily driven by 
the underlying disease rather than by its topical therapy. 
 Limitations of our pilot study include the small number 
of patients and the inherent heterogeneity of the clinical 
presentations of uveitis and raised intraocular pressure. Our 
study also does not assess the impact of preservatives, 
particularly BAK [11, 18] – as the availability of preser-
vative-free drops increases [19], it may be valuable to 
evaluate the levels of inflammation in similar patient groups 
receiving only unpreserved drops in a further study. 
Nevertheless, we conclude from our pilot study that the 
topical administration of prostaglandin analogues in patients 
with uveitic glaucoma is unlikely to increase the level of 
conjunctival inflammation and is therefore unlikely to 
prejudice later filtration surgery. 
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Fig. (2). Tear sample markers of inflammation. Tear samples were obtained using capillary tubes, stained, and assessed using multiplex 
flow cytometry. Nil, no topical medication; PG, prostaglandin analogues only; CS, corticosteroids only; PG+CS, prostaglandin analogues 
and corticosteroids concurrently. The mean ± the standard error of the mean of the detected concentrations is presented. There were no 
statistically significant differences between the groups. 
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